[Solved] Clomipramine and truffle ceremony

The combination of clomipramine (a tricyclic antidepressant, TCA) and psilocybin is currently being by us not recommended. Although SSRIs can now be combined with psilocybin in some cases, this does not automatically apply to TCAs such as clomipramine.

The reason for this is twofold: firstly, there is a lack of scientific research regarding the safety of this combination. Secondly, clomipramine, like other TCAs, appears to influence the action of psilocybin on serotonin receptors to such an extent that the effect becomes unpredictable. In some cases, this could even entail health risks, such as an increased risk of serotonin syndrome.

Triptherapie recommends in this case to to taper off the medication in consultation with the treating physician. Just two weeks after complete abstinence While taking clomipramine, a psilocybin session may be scheduled. There is also the possibility of switching to an SSRI as an interim solution, provided this is done in consultation with a doctor.

For people with depressive symptoms, a psilocybin session still offer a powerful alternative, provided one is well prepared and medication-free. The Triptherapie program focuses on a holistic approach, where lifestyle, nutrition, and neurochemical support take center stage, both before and after the psychedelic experience.

You can read more about this specific interaction in the article. Psilocybin and antidepressants, and also on the forum topic about TCAs such as clomipramine you will find experience-based insights and advice.

Would you like to know if and when you can participate in a truffle ceremony according to our assessment? Then fill out the intake via this link.

Yes, participate in a truffle ceremony can when you use clomipramine, but it is pharmacological more unpredictable and risky than with SSRI use. The most important point of attention is pharmacodynamic serotonergic overlap (TCA + psilocybin) with the possibility of enhanced or altered trip intensity and – in theory – a higher risk of serotonergic side effects. Psilocybin in itself gives no relevant increased risk of serotonin syndrome; that risk arises primarily in combination with other serotonergic agents (such as TCAs/MAOIs) and appears low with SSRIs/SNRIs, although caution is still advised.

Why clomipramine + psilocybin is a special case

Clomipramine (a TCA) strongly inhibits serotonin reuptake (SERT) and has broad receptor affinity; it can, among other things, lead to QTc prolongation and arrhythmia lead and causes pronounced anticholinergic and adrenergic side effects. Psilocybin is converted into psilocin, a 5-HT₂A agonist that causes the psychedelic experience. The combination means additive serotonergic stimulation, plus possible cardiovascular cumulative effect (psilocybin briefly increases heart rate and blood pressure).

Historical case studies involving LSD suggest that tricyclic antidepressants (inclusive clomipramine) the psychedelic response can strengthen and bring forward. This has not been systematically investigated for psilocybin, but pharmacologically, a similar direction seems likely.

Serotonin syndrome: what does the literature say?

For classic psychedelics like psilocybin, the risk of serotonin syndrome is very low in itself. In reviews, it is explicitly stated that it together with SSRIs/SNRIs likely risk gives; exceptions concern combinations with MAOI-containing substances (such as ayahuasca) that do increase the risk. TCAs are assessed more critically as a precaution due to their strongly serotonergic and cardiotoxic profile.

Small controlled studies show that psilocybin under escitalopram pretreatment is easy to bear, with no signs of serotonergic toxicity, and even fewer “negative” subjective effects, while the positive effects remain largely intact.

Half-lives and 5×-half-life (practical for planning)

For interactions, the especially duration presence relevant.

1. Clomipramine: t½ approximately 19–37 hours; active metabolite desmethylclomipramine 54–77 hours. Five half-lives ≈ 4–8 days (clomipramine) and 11–16 days (desmethylclomipramine).

2. Psilocin (from psilocybin): oral t½ typical ~2–4.8 hours (studies report ~1.5–4.7 hours); 5× t½ ≈ 8–24 hours.

Specifically: psilocin is after < 1 day practically elaborated; clomipramine and its metabolite remain 1–2 weeks pharmacologically relevant presence. This means that after not having taken clomipramine for approximately 2 weeks, the psilocybin or psilocin is virtually unaffected, and you could restart the medication one day after using psilocybin. 

What does this mean for participation in a truffle ceremony or the use of psilocybin (truffle/magic mushrooms)?

1) Participate without medication adjustment

This is possible, but requires extra caution: expect a unpredictable or reinforced response, pay attention cardiovascular parameters and be alert to serotonergic alarm symptoms (agitation, tremor, hyperreflexia, sweating, fever). Although psilocybin alone poses little risk of serotonin syndrome, that risk is theoretically higher with TCAs than with SSRIs. Organize medical screening, avoid MAOIs and other serotonergic agents (e.g. tramadol, linezolid, triptans) during the run-up, and start at a low dose.

2) Switching to an SSRI and then join in

Scientific reports and small studies indicate that psilocybin reasonably safe can be combined with a SSRI, and that the positive effects can largely be preserved, while some unwanted acute effects actually to decrease. Practical disadvantage: SSRIS be able to the subjective intensity what flatten. If safety is a priority, this is often the preferred route above continue with clomipramine. The switch must be gradual and under prescriber supervision, with attention to QTc/arrhythmia risk and withdrawal symptoms.

3) Wash-out of clomipramine before a ceremony

If you wish to pause clomipramine (in consultation with your doctor) to minimize interactions, apply at least the 5×-half-life: practical ~1–2 weeks after the last dose, because the active metabolite circulates for a long time. Many clinical protocols require a taper + wash-out by ≥ 2 weeks (longer with fluoxetine) before psychedelic sessions. Note: stopping is possible withdrawal symptoms or relapse administer; do this only under medical supervision.

Cardiovascular and general safety

Psilocybin can temporarily heart rate and blood pressure increase; with TCA use, extra cardiac caution appropriate given the known QTc/arrhythmia risk of clomipramine. Clinical reviews describe psilocybin in controlled doses as relatively safe, but recommend monitoring, especially in cases of comorbidity or polypharmacy.

Pharmacokinetics: few true “CYP collisions”, mainly dynamics

Psilocin is primarily produced in humans glucuronidated (UGT1A9/UGT1A10) and further demolished to a small extent; only ~1.5–3.4% returns as unchanged psilocin in urine. This means that real CYP-mediated interactions with clomipramine not prominent are; the The interaction is primarily pharmacodynamic. (serotonergic and autonomic effects).

Conclusion and practical advice

You can participating in a truffle ceremony while using clomipramine, but it is less ideal in terms of medical content than with an SSRI or after an adequate washout. The combination of TCA and psilocybin has a unpredictable, possibly reinforced psychedelic response and asks stricter security (screening, monitoring, lower starting dose, avoidance of additional serotonergic agents). Psilocybin does not increase the risk of serotonin syndrome in itself; the risk arises primarily from combinations, where SSRI/SNRI combination in the literature probably little risk gives, and TCAs as a precaution more critical be assessed. Therefore, consider – if the psychiatric situation permits – in consultation with your prescriber a switch to an SSRI or a controlled wash-out before participation.